Navigation Links
Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
Date:10/2/2007

ans to advance the development of Celacade(TM), plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the avail
'/>"/>
SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing of ... and warrants to purchase up to an aggregate 3,500,000 shares ... share and $.01 per warrant.  The warrants have a per ...
(Date:12/24/2014)... GMO corn cases filed across the United ... process of being consolidated in a Kansas federal court for ... MIR 162 Corn Litigation, MDL No. 2591 in the U.S. ... the Syngenta GMO corn multidistrict litigation (MDL) has been handed ...
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... SCOTTSDALE, Ariz., March 17, 2011 Delta Point, Inc., ... and developing business relationships, has named Ed Weimer as ... numerous awards for his ability to highly motivate, develop ... providing the strategic vision to contribute to the organization,s ...
... 2011 Genesis Biopharma, Inc. (OTC Bulletin ... targeted cancer therapies, today announced it has appointed William ... Andrews has three decades experience in biotechnology research and ... of Sierra Sciences, LLC, a company he founded in ...
... 2011 A first-of-its-kind study of gene therapy in ... all patients who received the treatment had "clinically meaningful ... "The study demonstrates that the promise of ... says study lead author and co-principal investigator Peter LeWitt, ...
Cached Biology Technology:Ed Weimer Joins Delta Point, Inc. as Executive Account Director 2Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors 2Study: 'Meaningful improvements' Using Gene Therapy in Parkinson's Disease 2Study: 'Meaningful improvements' Using Gene Therapy in Parkinson's Disease 3
(Date:12/22/2014)... (NASDAQ: NXTD and NXTDW) ("NXT-ID" or the ... commerce market, announces it has retained famous pickpocket, entertainer and ... CES debut of the Wocket™ biometric smart wallet.  ... booth January 6th and 7 th , 2015, demonstrating some ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... http://photos.prnewswire.com/prnh/20130307/600769 ... introduced the fingerprint reading feature with the iPhone 5S. ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... transmitted diseases (STDs) requires treatment of the sexual partners ... infected men with antibiotics to give their partners is ... the partners, according to an article in the Sept. ... Men with chlamydia or gonorrhea were more likely to ...
... into a tumor, seal the exits and detonate a ... cells unscathed. , MIT researchers have designed a nanoparticle ... "nanocell" proved effective and safe, with prolonged survival, against ... mice. , The work will be reported in the ...
... A new study released in Science (via Science Express ... in the diversity of fish in the open ocean ... Teasing apart the effects of climate change and fishing ... clear link to overfishing and highlight a surprising global ...
Cached Biology News:New study: Sexually transmitted disease treatment can be effectively administered by sex partners 2New study: Sexually transmitted disease treatment can be effectively administered by sex partners 3MIT engineers an anti-cancer smart bomb 2Scientists discover global pattern of big fish diversity in open oceans 2Scientists discover global pattern of big fish diversity in open oceans 3Scientists discover global pattern of big fish diversity in open oceans 4Scientists discover global pattern of big fish diversity in open oceans 5
... 0.2ml thermal cycler blocks, 96-well PCR plate, 0.3ml ... heat seals), Cut-away corner , Fits all 0.2ml ... 3700 capillary sequencers, Clear well bottom for sample ... Adhesive Films and Foils, Heat Seals and Flat ...
... are designed for protein pull-down ... sphingosine binding proteins. An order ... of agarose beads with 10 ... the terminus of the alkyl ...
... Competitor Assay Kits provide a sensitive and ... AR ligands using fluorescence polarization (FP). The ... protein tagged with His and GST [AR-LBD ... ligand (Fluormone AL Green in the green ...
... Plus is a chemiluminescent signal enhancing ... to boost the signal obtained with ... kits. ChemiLucent™ Plus is derived from ... conjugated complex- or chemiluminescent substrate enhancers, ...
Biology Products: